Sinopep-Allsino Biopharmaceutical Co. Ltd. A (SHG:688076) — Market Cap & Net Worth
Market Cap & Net Worth: Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076)
Sinopep-Allsino Biopharmaceutical Co. Ltd. A (SHG:688076) has a market capitalization of $1.27 Billion (CN¥8.70 Billion) as of August 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #7852 globally and #1778 in its home market, demonstrating a 1.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sinopep-Allsino Biopharmaceutical Co. Ltd. A's stock price CN¥27.52 by its total outstanding shares 316051897 (316.05 Million). See 688076 capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Market Cap History: 2021 to 2026
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $1.87 Billion to $1.27 Billion (-17.70% CAGR).
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.90x
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap is 0.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.33x
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap is 5.33 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.87 Billion | $643.87 Million | $115.39 Million | 2.91x | 16.25x |
| 2022 | $1.05 Billion | $651.29 Million | $129.11 Million | 1.61x | 8.11x |
| 2023 | $2.06 Billion | $1.03 Billion | $162.94 Million | 1.99x | 12.65x |
| 2024 | $2.40 Billion | $1.62 Billion | $404.39 Million | 1.48x | 5.94x |
| 2025 | $1.74 Billion | $1.94 Billion | $327.00 Million | 0.90x | 5.33x |
Competitor Companies of 688076 by Market Capitalization
Companies near Sinopep-Allsino Biopharmaceutical Co. Ltd. A in the global market cap rankings as of August 7, 2026.
Key companies related to Sinopep-Allsino Biopharmaceutical Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #544 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #571 globally with a market cap of $47.50 Billion USD ( ₩70.08 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.03 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $772.11 |
| #544 | Argen-X | BR:ARGX | $49.55 Billion | €753.80 |
| #571 | Samsung Biologics Co Ltd | KO:207940 | $47.50 Billion | ₩1514000.00 |
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap moved from $1.87 Billion to $ 1.27 Billion, with a yearly change of -17.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.27 Billion | -27.00% |
| 2025 | CN¥1.74 Billion | -27.39% |
| 2024 | CN¥2.40 Billion | +16.47% |
| 2023 | CN¥2.06 Billion | +97.02% |
| 2022 | CN¥1.05 Billion | -44.18% |
| 2021 | CN¥1.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 7th, 2026 the market cap of Sinopep-Allsino Biopharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.27 Billion USD |
| MoneyControl | $1.27 Billion USD |
| MarketWatch | $1.27 Billion USD |
| marketcap.company | $1.27 Billion USD |
| Reuters | $1.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more